Cardiovascular Systems, Inc. (CSII - Free Report) delivered earnings per share (EPS) of 4 cents in fourth-quarter fiscal 2019, down 63.6% year over year. The reported figure was in line with the Zacks Consensus Estimate.
For the full year, loss per share came in at a cent, reflecting a sharp decline from the year-ago earnings of 5 cents.
Cardiovascular Systems’ revenues of $68.2 million in the fourth quarter mark a 15.4% year-over-year increase. Meanwhile, the top line beat the Zacks Consensus Estimate by 3.33%.
For the full year, revenues totaled $248 million, up 14.3% from a year ago.
In the quarter under review, global Coronary device revenues jumped 24% year over year to $20 million. Total U.S. revenues increased 13% to $65.7 million. Domestic coronary revenues grew 16%, primarily driven by expanded unit volumes. Domestic peripheral revenue registered growth of 12% to $48.2 million. International revenues totaled $2.5 million.
Gross margin in the reported quarter was 80.3%, down 145 basis points (bps) year over year.
Meanwhile, selling, general and administrative (SG&A) expenses rose 16.2% to $43.9 million plus research and development (R&D) expenses escalated 41.8% to $9.5 million. As a result, operating expenses increased 20.1% to $53.5 million. Operating margin in the reported quarter contracted 454 bps to 1.8%.
The company exited fiscal 2019 with cash and cash equivalents of $74.2 million compared with $116.3 million at the end of fiscal 2018.
Cardiovascular Systems initiated its fiscal 2020 guidance. The company projects revenues within $278-$283 million for fiscal 2020. The Zacks Consensus Estimate for fiscal 2020 revenues is pegged at $277.2 million, just below the company's view.
Moreover, the company anticipates gross profit margin within 79-80%.
Cardiovascular Systems exited fiscal 2019 with in-line earnings and revenue beat. We are upbeat about the year-over-year uptick in both Coronary and peripheral device revenues within the company’s domestic market. It is making concerted efforts in product innovation through R&D investments. The acquisition of WIRION Embolic Protection System during the quarter buoys optimism. The enrollment of the first patient inREACH PVI Clinical Study is encouraging as well.
On the flip side, contraction in both margins is disappointing. Also, Cardiovascular Systems faces cut-throat competition in the niche space.
Zacks Rank and Key Picks
Cardiovascular Systems currently carries a Zacks Rank #5 (Strong Sell).
A few better-ranked companies, which posted solid results this earnings season, are Stryker Corporation (SYK - Free Report) , Baxter International Inc. (BAX - Free Report) and Intuitive Surgical, Inc. (ISRG - Free Report) .
Baxter delivered second-quarter 2019 adjusted EPS of 89 cents, which surpassed the Zacks Consensus Estimate of 81 cents by 9.9%. Revenues of $2.84 billion beat the Zacks Consensus Estimate of $2.79 billion by 1.9%. The company holds a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Stryker delivered second-quarter 2019 adjusted EPS of $1.98, beating the Zacks Consensus Estimate by 2.6%. Revenues of $3.65 billion surpassed the Zacks Consensus Estimate by 1.4%. The company carries a Zacks Rank of 2.
Intuitive Surgical reported second-quarter 2019 adjusted EPS of $3.25, which beat the Zacks Consensus Estimate of $2.85. Revenues were $1.1 billion, surpassing the Zacks Consensus Estimate of $1.03 billion. The company has a Zacks Rank #1.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity. A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
See 7 breakthrough stocks now>>